About
AIATELLA, founded in 2022 in Helsinki, Finland, develops automated cardiovascular imaging AI tools for early detection of heart disease.
Full tier & rationale — an SVTR Intelligence benefit
Capital graph
Investor· 4
Founders / team· 1
Funding history
- 2025-06Seed$2M
Investors · Harjavalta Ventures, Business Finland, Specialist VC, Nordic Science InvestmentsSource · SVTR Weekly #108
Comparable companies· by market
This company
BusinessLatest roundTotal raisedDate- AIATELLA
AI tools for automated cardiovascular imaging analysis for early detection of heart disease
Seed · $2M · 2025-06
$2M
United States
BusinessLatest roundTotal raisedDate- DeepLook Medica
Automates image measurement and segmentation across medical imaging platforms
Seed · $2M · 2024-02
$2M - Ezra
Full-body MRI scans for early detection of cancer and other health conditions
Seed · $61M · 2026-03
$61M - Onepot
Small-molecule synthesis for drug discovery for biopharma companies (AI + automated synthesis)
Seed · $13M · 2025-11
$13M
China
BusinessLatest roundTotal raisedDate- 冰晶医智
Developer of cardiovascular interventional imaging/intracardiac echocardiography (ICE) devices
Series A · $139M · 2026-06
$139M - 柏视医疗
AI medical imaging analysis platform
Series B · $13M · 2024-02
$13M - Coherence Biotech Co. Ltd.
Lab automation: the Keystone™ benchtop all-in-one system combines culturing, intervention and microscopy imaging into uninterrupted multi-day cell/organoid experiments and uses AI vision to identify, count and track cells, generating structured experimental data for AI drug discovery
—
Europe
BusinessLatest roundTotal raisedDate- CardiaTec
Uses AI and large-scale multi-omics data to discover new therapies for cardiovascular disease
Seed · $7M · 2024-09
$7M - DESKi
AI tools that automatically analyze echocardiograms to assist heart disease diagnosis
Seed · $6M · 2025-06
$6M - ScienceMachine
AI bioinformatics agents to automate experiments and data analysis
Pre-Seed · $4M · 2025-07
$4M
Other / unspecified
BusinessLatest roundTotal raisedDate- Aidoc
Provides a clinical AI imaging analysis platform that uses AI to read CT, X-ray and other medical images, flag abnormalities and assist with case prioritization
Series D+ · $500M · 2026-05
$500M - Mediwhale
AI analysis of retinal images to predict cardiovascular, kidney and eye disease risk
Series A · $12M · 2024-09
$12M - Qure.AI
Uses AI to analyze medical images and detect disease
Undisclosed · $65M · 2024-09
$65M
Confirmed rounds only. Matched on subsector, sector, stage and funding scale — each verifiable on the company profiles.
Investors that may fit
Andreessen Horowitz
24 Life Sciences deals in the last 24 months · 11 at a nearby stage
Request intro →Ranked by each firm’s deals in this sector over the last 24 months, weighted by nearby stage and shared geography. Indicative only — no rating judgment.